Get started
Author

Mariela Sivina

Observed names: M Sivina, M. Sivina, Sivina M
ORCID: 0000-0003-0091-0648
Observed ORCID: 0000-0003-0091-0648
OpenAlex ID: A5083315699
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
2011 · Julia Hoellenriegel, Sarah A. Meadows, et al. · Blood · 549
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
2016 · Jan A. Burger, Dan A. Landau, et al. · Nature Communications · 346
PDF
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
2009 · Antonina V. Kurtova, Kumudha Balakrishnan, et al. · Blood · 319
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
2009 · Maite P. Quiroga, Kumudha Balakrishnan, et al. · Blood · 237
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
2018 · Jan A. Burger, Mariela Sivina, et al. · Blood · 217
PDF
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
2017 · Dan A. Landau, Clare Sun, et al. · Nature Communications · 176
PDF
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
2011 · Xavier C. Badoux, Michael J. Keating, et al. · Blood · 165
The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cells
2006 · H. Daniel Lacorazza, Takeshi Yamada, et al. · Cancer Cell · 157
PDF
Molecular map of chronic lymphocytic leukemia and its impact on outcome
2022 · Binyamin A. Knisbacher, Ziao Lin, et al. · Nature Genetics · 154
PDF
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
2012 · J Hoellenriegel, G P Coffey, et al. · Leukemia · 145
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
2010 · Mariela Sivina, Elena Hartmann, et al. · Blood · 127
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
2017 · Qingsong Yin, Mariela Sivina, et al. · The Journal of Immunology · 116
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
2017 · Jan A. Burger, Kelvin W. Li, et al. · JCI Insight · 95
PDF
The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
2013 · Stefania Fiorcari, Wells S. Brown, et al. · PLoS ONE · 86
PDF
The bruton tyrosine kinase inhibitor ibrutinib ( PCI ‐32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach
2014 · Mariela Sivina, Robert J. Kreitman, et al. · British Journal of Haematology · 79
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
2015 · Koichi Takahashi, Mariela Sivina, et al. · British Journal of Haematology · 73
PDF
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
2016 · Preetesh Jain, Michael J. Keating, et al. · Clinical Cancer Research · 56
Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
2016 · C. Vitale, I. E. Ahn, et al. · Haematologica · 46
Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia
2012 · M Sivina, E Hartmann, et al. · Leukemia · 42
Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B‐cell acute lymphoblastic leukaemia
2016 · Shubhchintan Randhawa, Byung S. Cho, et al. · British Journal of Haematology · 41
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia
2016 · Elisa ten Hacken, Mariela Sivina, et al. · The Journal of Immunology · 39
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations
2021 · Mariela Sivina, Ekaterina Kim, et al. · Blood · 27
PDF
CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia
2020 · Mariela Sivina, Lianchun Xiao, et al. · Leukemia · 25
A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia
2019 · Leslie A. Andritsos, John C. Byrd, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 24
Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia
2015 · Betty Lamothe, Fabiola Cervantes-Gomez, et al. · Blood · 23
Works count: 83
Citation count: 3,638
H-index: 24
I10-index: 38
Year
Topic
Type